ELCC 2018 | Transforming outcomes in advanced lung cancer: immunotherapy in unselected patients

Martin Reck

Immunotherapeutic agents are increasingly becoming incorporated into clinical practice; however, there is still much to learn, including their optimal combinations, sequencing and usage. In this interview, Martin Reck, MD, PhD, of the Lung Clinic Grosshansdorf, Grosshansdorf, Germany, discusses whether we can improve the efficacy of immunotherapy in lung cancer patients who have not been selected for their high PD-L1 expression. This video was recorded at the European Lung Cancer Congress (ELCC) 2018, held in Geneva, Switzerland.

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter